||COM STK USD0.01 (DI/REG S)
||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Maxcyte (DI/S) Share Discussion Threads
Showing 26 to 49 of 50 messages
I find it impossible to value this one, I bought primarily for the tax breaks as you know. I dont really believe in reading tea leaves, but I suspect the chartists would have said it was overdue a big correction at 280p, mind you they would probably have told you the same thing at 140p and 210p on the way up (and it didnt happen). This is one share where I havent been able to talk to the ,management, so all I have to go on is what is in the public domain.
The Trinity Development research notes are a useful read if you haven't already seen them
you probably have studied this one thoroughly- i have been watching it and i notice it is down 30pc- but no clue as to whether this presents an opportunity to enter? just interested in your take!|
|Let sleeping dogs lie timbo003!|
|This is now a 4 bagger since the IPO, or a 5.5 bagger if you take into account the EIS tax relief.
I find it quite extraordinary that there is no interest here. I would have thought at least the Scancell crowd might have had a sniff around, given that MaxCyte's business is all about Electroporation and Scancell's lead drug (SCIB1) requires electroporation for effective delivery.|
|Here's a date for your diaries
23rd March MaxCyte will be presenting at the Proactiveinvestor evening at the Chesterfield Hotel in Mayfair,
It's free and you get fed and watered afterwards, so I've booked my place.
|Another good day, market cap now just a tad over £100m, presumably it will now get on a few more radar screens.|
|Thanks for that dave4p, there is also a new note available from Trinity Delta here:
|The publication referred to in today's RNS appears to concern the work referred to in Panmure Gordon's morning note from last week.
Up again today, now 3X the IPO price, or over 4X the price paid by IPO participants who qualified for EIS tax reliefs (i.e. 49p/share).|
|Yes and from memory 50+ licencees,(up from 30+ at the time of the float).|
That note from Panmure puts the rise into context, so they are now looking at a new platform which is likely to be of considerable interest to big pharma and it sounds like Maxcyte are the only shop in town|
|And the following update by PG:
|The Ft has named it as the top pharma small cap stock pick of 2017.|
|Up today again and I am still none the wiser
There is nothing obvious on their twitter feed, other than they will be presenting at Biotech show case next week which surely wouldn't account for this rise
|Time for another animated gif!
I have no idea why these are up today, or why no one else in the ADVFN and LSE cyber communities have shown any interest in this one, but I am quite happy to be a Norman no mates if the performance continues like this|
|New video of CEO Doug Doerfler discussing the latest announcement regarding MaxCytes's CARMA platform:
|don't worry timbo it will soon drift back down again|
|Drifting up for no easily discernable reason, normally my AIM shares do the opposite in the absence on news. If only they were all like this one (sigh!)|
|>>davep4, indeed. I wish I had as much in this one as have in Cyan. I seem to have an exceptional talent for underinvesting in shares which take off like this one!|
|timbo003 let's hope Cyan does the same soon!|
|This week's (unexpected) performance has to be worth an animated gif!
As much as I would have liked to have attended the AGM yesterday, I think travelling over to the Maryland in the US would have been beyond the call of duty given the size of my modest holding|
I hope they do better than the most recent "Best Technology" award winners, for example:
* 2015 award winner: Advanced Oncotherapy (down > 45% in 12 months)
* 2014 award winner: Rex Bionics (down > 85% in 24 months)
* 2013 award winner: Wandisco (down > 85% in 36 months).
|Hey guys, you have just won the Aim Technology Company of the Year award for 2016, don't all cheer at once :)|